Puma Biotechnology | PBYI - Interest Expense On Debt


Puma Biotechnology reported $3.37M in Interest Expense on Debt for its fiscal quarter ending in June of 2024.





Interest Expense On Debt Change Date
Agios Pharmaceuticals USD 1.39B 85.53M Sep/2025
Alnylam Pharmaceuticals USD 129.34M 84.94M Dec/2025
Amgen USD 653M 32M Dec/2025
Biogen USD 72.6M 12.6M Jun/2025
BioMarin Pharmaceutical USD 2.78M 199K Dec/2025
Daiichi Sankyo JPY 2.16B 1.33B Dec/2025
Esperion Therapeutics USD 15.08M 1.36M Sep/2024
Exelixis USD 23.4M 3.9M Sep/2023
Gilead Sciences USD 255M 1000K Dec/2025
Glaxosmithkline GBP 177.95M 6.05M Sep/2025
Incyte USD 582K 10K Dec/2025
MacroGenics USD 3.34M 2.54M Sep/2025
Moderna USD 12.14B 12.13B Sep/2025
Novartis USD 281M 8M Sep/2025
Pfizer USD 711M 59M Dec/2025
PTC Therapeutics USD 50.58M 2.59B Dec/2025
Puma Biotechnology USD 3.37M 11K Jun/2024
Regeneron Pharmaceuticals USD 12.2M 7.1M Dec/2025
Roche Holding CHF 304M 7.5M Jun/2025
Sangamo BioSciences 97.56M 11.39M Jun/2025
Sarepta Therapeutics USD 7.56M 2.33M Sep/2025
Takeda JPY 123.63B 40.49B Dec/2025
TG Therapeutics USD 6.53M 187K Dec/2025
Ultragenyx Pharmaceutical USD 19M 4.85M Dec/2025
Vanda Pharmaceuticals 601.14M 23.61M Sep/2025
Vertex Pharmaceuticals USD 3.3M 0 Dec/2025